Obsidian Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2015-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.obsidiantx.com
Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)Safety and Efficacy of OBX-115 in Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Tumor SkinLung CancerNon Small Cell Lung CancerMelanomaMetastatic Lung CancerMetastatic MelanomaMetastatic Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2023-09-29
- Last Posted Date
- 2025-08-29
- Lead Sponsor
- Obsidian Therapeutics, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT06060613
- Locations
- 🇺🇸
The Angeles Clinic and Research Institute (Melanoma), Los Angeles, California, United States
🇺🇸USC Norris Comprehensive Cancer Center (Melanoma/NSCLC), Los Angeles, California, United States
🇺🇸Stanford Cancer Institute (Melanoma/NSCLC), Stanford, California, United States
News
No news found